For research use only. Not for therapeutic Use.
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC)[1].
| Catalog Number | I043745 |
| CAS Number | 790245-61-3 |
| Synonyms | 2-(6,7-dihydro-5H-cyclopenta[f][1]benzofuran-3-yl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide |
| Molecular Formula | C17H16N2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C17H16N2O2S/c1-10-8-18-17(22-10)19-16(20)7-13-9-21-15-6-12-4-2-3-11(12)5-14(13)15/h5-6,8-9H,2-4,7H2,1H3,(H,18,19,20) |
| InChIKey | IELCYEUTXLYDOV-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(S1)NC(=O)CC2=COC3=C2C=C4CCCC4=C3 |
| Reference | [1]. Dieter SM, et al. Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 2021;36(3):109394. |
